Biological activity of dihydroartemisinin in canine osteosarcoma cell lines

被引:26
作者
Hosoya, Kenji [1 ]
Murahari, Sridhar [1 ]
Laio, Albert [2 ]
London, Cheryl A. [1 ,2 ]
Couto, C. Guillermo [1 ]
Kisseberth, William C. [1 ]
机构
[1] Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Dept Vet Biosci, Columbus, OH 43210 USA
关键词
D O I
10.2460/ajvr.69.4.519
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Objective-To evaluate the biological activity of dihydroartemisinin on canine osteosarcoma cell lines in vitro. Sample Population-4 canine osteosarcoma cell lines. Procedures-Cell viability assays were performed on canine osteosarcoma cell lines CSCA2, OSCA16, OSCA50, and D17 after 24, 48, and 72 hours of treatment with dihydroartemisinin at concentrations of 0.1 to 100 mu M. Apoptosis was assessed by use of an ELISA for free nuclosomal DNA fragmentation and by western blot analysis for cleavage of caspase 3. Cell cycle analysis was performed by use of staining with propidium iodide and flow cytometry. Detection of reactive oxygen species (ROS) was conducted in the D17 cell line by use of 6-carboxy-2',7'-dihydrofluorescein diacetate and flow cytometry. Results-The concentration of dihydroartemisinin required for 50% inhibition of cell viability (IC50) was achieved in all 4 canine osteosarcoma cell lines and ranged from 8.7 to 43.6 mu M. Induction of apoptosis was evident as an increase in nucleosomal DNA fragmentation, cleavage of caspase 3, and an increase in the population in the sub G(0)/G(1) phase of the cell cycle detected by flow cytometry. Exposure to dihydroartemisinin also resulted in a decrease in the G(0)/G(1) population. Iron-dependent generation of ROS was detected in dihydroartemisinin-treated D17 cells; ROS generation increased in a dose-dependent manner. Conclusions and Clinical Relevance-Incubation with dihydroartemisinin resulted in biological activity against canine osteosarcoma cell lines, which included induction of apoptosis and arrest of the cell cycle. Clinical trials of dihydroartemisinin in dogs with osteosarcoma should be conducted.
引用
收藏
页码:519 / 526
页数:8
相关论文
共 35 条
  • [1] Artemisinin-derived sesquiterpene lactones as potential antitumour compounds: Cytotoxic action against bone marrow and tumour cells
    Beekman, AC
    Wierenga, PK
    Woerdenbag, HJ
    Van Uden, W
    Pras, N
    Konings, AWT
    El-Feraly, FS
    Galal, AM
    Wikstrom, HV
    [J]. PLANTA MEDICA, 1998, 64 (07) : 615 - 619
  • [2] Berger TG, 2005, ONCOL REP, V14, P1599
  • [3] China Cooperative Research Group on Qinghaosu and its Derivatives as Antimalarials, 1982, J TRADIT CHIN MED, V2, P31
  • [4] Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo
    Disbrow, GL
    Baege, AC
    Kierpiec, KA
    Yuan, H
    Centeno, JA
    Thibodeaux, CA
    Hartmann, D
    Schlegel, R
    [J]. CANCER RESEARCH, 2005, 65 (23) : 10854 - 10861
  • [5] Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron
    Efferth, T
    Benakis, A
    Romero, MR
    Tomicic, M
    Rauh, R
    Steinbach, D
    Häfer, R
    Stamminger, T
    Oesch, F
    Kaina, B
    Marschall, M
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2004, 37 (07) : 998 - 1009
  • [6] Molecular modes of action of artesunate in tumor cell lines
    Efferth, T
    Sauerbrey, A
    Olbrich, A
    Gebhart, E
    Rauch, P
    Weber, HO
    Hengstler, JG
    Halatsch, ME
    Volm, M
    Tew, KD
    Ross, DD
    Funk, JO
    [J]. MOLECULAR PHARMACOLOGY, 2003, 64 (02) : 382 - 394
  • [7] mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether
    Efferth, T
    Olbrich, A
    Bauer, R
    [J]. BIOCHEMICAL PHARMACOLOGY, 2002, 64 (04) : 617 - 623
  • [8] Efferth T, 1996, ARZNEIMITTEL-FORSCH, V46, P196
  • [9] Efferth T, 2001, INT J ONCOL, V18, P767
  • [10] JIANG JB, 1982, LANCET, V2, P285